Udenafil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Udenafil
Udenafil.svg
Systematic (IUPAC) name
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
Pharmacokinetic data
Biological half-life 7.3–12.1 hours
Identifiers
CAS Number 268203-93-6 N
ATC code G04BE11 (WHO)
PubChem CID 6918523
DrugBank DB06267 YesY
ChemSpider 5293720 YesY
UNII L5IB4XLY36 YesY
KEGG D10027 N
Chemical data
Formula C25H36N6O4S
Molar mass 516.657 g/mol
 NYesY (what is this?)  (verify)

The drug udenafil, marketed under the trade name Zydena, is within the PDE5-inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, undenafil was developed by Dong-A Pharmaceutical.[1] With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines;[3] in the United States, it has not been approved by the U.S. Food and Drug Administration.

References[edit]

  1. ^ Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
  2. ^ "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
  3. ^ [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com